Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PM8002 plus chemotherapy as second-line treatment for unresectable neuroendocrine tumors
CTR20223125Phase 2Active
- Sponsor
- Biotheus
- Start
- May 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in apudoma (NET), neuroendocrine carcinoma (NEC), sponsored by Biotheus. Started May 2023; status: active.
02
Drugs
pumitamig
03
Conditions
apudoma (NET)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20223125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223125.